Convatec Group PLC (LSE: CTEC), the FTSE 100 medical products company focused on chronic condition management, has upgraded its full-year 2026 revenue growth guidance to 6.25–7.0% from a previous range of 5.5–6.5%, citing accelerating second-half momentum across its Infusion Care and Continence Care divisions. The ten-month trading update to 31 October 2026 reports year-to-date organic revenue growth of 6.6% excluding InnovaMatrix, with reported growth of 4.8%. Chief Executive Jonny Mason attributed the stronger performance to improved manufacturing execution, new product launches, and continued market share gains across all four business segments.
Key Points
- Convatec Group PLC (CTEC) — FTSE 100 global medical products company operating in around 90 countries
- FY26 Group organic revenue growth guidance upgraded to 6.25–7.0%, up from 5.5–6.5% previously
- YTD organic growth ex-InnovaMatrix of 6.6%; Infusion Care accelerated to double-digit growth; InnovaMatrix FY26 revenue now expected at approximately $5m versus prior guidance of $5–10m
- Investors may be watching whether new product launches — including Natura Body in mid-2027 and ConvaNiox US trial results expected in 2027 — sustain medium-term 6–8% organic revenue growth targets
Infusion Care and Continence Care Drive Second-Half Revenue Acceleration at Convatec
Infusion Care accelerated to double-digit growth year-to-date, driven by faster second-half diabetes growth and continued strong demand from AbbVie's Parkinson's disease treatment. The announcement states that improved manufacturing execution delivered increased volumes, ahead of new capacity coming online in 2027. Continence Care also upgraded its outlook to mid-to-high single digit growth for FY26, an improvement on the previous mid-single digit expectation, supported by increased US new patient volumes, further strong growth outside the United States, and ongoing share gains from the GentleCath Air for Women compact catheter.
Ostomy Care and Advanced Wound Care Maintain Mid-Single Digit Growth Trajectory
Ostomy Care delivered mid-single digit growth year-to-date, consistent with its first-half performance. The Esteem Body one-piece soft convex product continued to gain share, reaching approximately 15% segment share according to the announcement. The two-piece equivalent, Natura Body, remains on track to launch in mid-2027, which the company states will close a gap in its soft convex portfolio considered essential for US growth. Advanced Wound Care delivered low-to-mid single digit growth ex-InnovaMatrix, with ConvaFoam gaining share and Aquacel AG+ Extra growing slightly ahead of soft markets.
InnovaMatrix Revenue Expectation Cut; Adjusted Operating Margin Guidance Unchanged at 23%
Convatec revised its FY26 InnovaMatrix revenue expectation down to approximately $5m from a prior range of $5–10m. Despite this reduction, the company reiterated its adjusted operating profit margin guidance of at least 23%, which incorporates an approximately 65 basis point adverse foreign exchange headwind and an approximately 90 basis point InnovaMatrix headwind. The company also flagged that cash costs of adjusting items have risen to approximately $30m from the previous $20m, and equity cash conversion is now expected at approximately 90% versus the prior expectation of approximately 100%.
Convatec Reiterates Medium-Term Targets and Confirms $200m Buyback on Track
The announcement reiterates medium-term targets of 6–8% organic revenue growth and double-digit adjusted EPS growth, with an aspiration to reach a mid-20s percent adjusted operating margin from 2027. The $200m share buyback programme remains on track to complete within FY26. Total capital expenditure is guided to the upper end of the $200–230m range, with growth capex also at the upper end of the $135–165m range as the company accelerates capacity expansion. Double-digit growth in adjusted EPS guidance for FY26 is unchanged.



Please wait processing your request...